Latest From Carmat SAS
Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.
Results Recap: Medtronic Highlights Data To Contrast With Recent Meta-Analysis That Sparked Drug-Coated Balloon Scrutiny
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from MedDeviceTracker, includes medical device trial results announced from Jan. 11 through Jan. 24. This week's list is dominated by results presentations from the Leipzig Interventional Course (LINC) in Leipzig, Germany, including trials of devices from Medtronic, Boston Scientific, Gore, Profusa, InspireMD, and Vessi.
Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.
- Implantable Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Carmat SAS
- Senior Management
Marcello Conviti, CEO
Patrick Coulombier, COO
Alain Carpentier, Scientific Dir.
- Contact Info
Phone: (33) 139 456 450
36 Ave. de l'Europe Immeuble
Velizy Villacoublay, 78140
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.